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PElectrophysiology and Heart Failure: Viewpoint
rophylactic Implantable
ardioverter-Defibrillator Therapy
n Patients With Left Ventricular Systolic Dysfunction
Pooled Analysis of 10 Primary Prevention Trials
umaraswamy Nanthakumar, MD,* Andrew E. Epstein, MD,‡ G. Neal Kay, MD,‡ Vance J. Plumb, MD,‡
ouglas S. Lee, MD†
oronto, Ontario, Canada; and Birmingham, Alabama
Strategies to decrease sudden cardiac death in patients with left ventricular systolic
dysfunction are evolving. Recent clinical trials have evaluated the role of prophylactic
implantable cardioverter-defibrillators (ICDs) in patients with and without additional risk
stratifiers. We pooled studies comparing treatment with and without ICDs from published
data and presented abstracts, irrespective of QRS duration and etiology of systolic dysfunc-
tion. On the basis of the available clinical trials, implantation of an ICD for primary
prevention of death provides a 7.9% absolute mortality reduction (p 0.003) in patients with
left ventricular (LV) systolic dysfunction who were receiving optimized medical therapy. This
finding was not sensitive to the exclusion of any individual trial. The ICD is an effective
primary preventative measure in patients who are at risk for death; however, the application
of this therapy needs to be individualized for the patient, similar to drug therapies in LV
systolic dysfunction. In health care settings without unlimited resources, optimal use of this
therapy will require better risk stratification methods or lowering of the initial device
cost. (J Am Coll Cardiol 2004;44:2166–72) © 2004 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.054Cardiology Foundation
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fudden cardiac death accounts for approximately 50% of the
ortality for patients with left ventricular (LV) systolic
ysfunction (decreased LV ejection fraction) (1). Because
he implantable cardioverter-defibrillator (ICD) is effective
n terminating ventricular tachycardia and fibrillation, it
akes intuitive sense that a strategy of prophylactic ICD
mplantation in patients with LV systolic dysfunction would
ecrease arrhythmic mortality (2). Whether this therapy
ould decrease total mortality is less obvious (3).
Although the number of published prospective clinical
rials of ICD implantation has been increasing, policy-
akers dealing with the financial burden of adopting
uch a strategy have restricted usage to retrospectively
dentified subgroups that may have the greatest benefit
4). This decision was mainly driven by a preliminary
eview of the Multicenter Automatic Defibrillator Im-
lantation Trial II (MADIT II), in which QRS duration
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ccepted August 16, 2004.120 ms was thought to be an important risk stratifier.
owever, subsequent analysis has questioned the validity
f excluding patients with QRS width 120 ms (5), as
he risk of sudden cardiac death in those patients is not
egligible and the mortality benefit of an ICD remains
tatistically significant. A review of the Multicenter
nsustained Tachycardia Trial (MUSTT) registry re-
ealed that the all-cause mortality of patients who were
imilar to those in the MADIT II trial was 65% over a
eriod of five years in patients with QRS duration 120
s and 46% in patients with QRS duration 120 ms. In
he MUSTT registry, the all-cause five-year mortality for
atients with a QRS duration 120 ms who were treated
ith an ICD was 17%, compared with 38% for patients
ith QRS duration 120 ms who were treated with an
CD. These analyses point out the potential weakness of
imiting ICD therapy to patients with QRS duration
120 ms. The pitfalls of post-hoc analysis that lead to
estriction of therapy to “high-risk” subgroups have been
ell described (6) and may have particular relevance to
CD therapy. In addition, as a consequence of the current
estrictions that limit reimbursement of prophylactic
CDs to patients with QRS width 120 ms, it is possible
hat some patients with a narrow QRS width may be
ubjected to unnecessary electrophysiology (EP) studies
or the purposes of risk stratification and reimbursement
7).
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December 7, 2004:2166–72 Implantable Cardioverter-Defibrillator TherapyThe ability of individual trials to assess all-cause mortality
enefit from prophylactic ICD therapy has been limited by
low baseline risk of death and inadequate power to detect
ortality differences between treatment groups (8). A
ooled analysis of all-cause mortality in available random-
zed studies of prophylactic ICD therapy in patients with
V systolic dysfunction would provide a more precise
stimate of survival benefit for patients with both ischemic
nd nonischemic causes of LV systolic dysfunction, without
elying on subgroup analysis.
Several trials and meta-analyses have addressed the use of
CDs for preventing death in patients with LV systolic
ysfunction who have never had an arrhythmic event. It has
een estimated from four randomized trials and one non-
andomized trial that prophylactic ICD implantation re-
uces the relative risk (RR) for death by approximately 28%
o 34% (2,3). When only the four randomized trials were
ncluded, the sensitivity analysis indicated that the benefit
as not robust; that is, the conclusion was sensitive to
xclusion of any one trial from the meta-analysis (3). Since
he publication of these analyses, data from five additional
rials have become available (9–13).
While a meta-analysis on the effect of prophylactic ICDs
n survival of patients with LV systolic dysfunction would
e the ideal way of evaluating the data, all of the trials would
rst have to be published. Thus, there will be a hiatus during
hich physicians caring for potential ICD recipients will
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AMIOVIRT  Amiodarone Versus Implantable
Cardioverter-Defibrillator
Randomized Trial
CABG-Patch  Coronary Artery Bypass Graft Patch
trial
CAT  Cardiomyopathy Trial
CI  confidence interval
COMPANION  Comparison of Medical Therapy,
Pacing, and Defibrillation in Patients
With Left Ventricular Systolic
Dysfunction trial
CRT  cardiac resynchronization therapy
DEFINITE  Defibrillators In Non-Ischemic
Cardiomyopathy Treatment
Evaluation trial
DINAMIT  Defibrillator In Acute Myocardial
Infarction Trial
EP  electrophysiology
ICD  implantable cardioverter-defibrillator
LV  left ventricular
MADIT  Multicenter Automatic Defibrillator
Implantation Trial
MUSTT  Multicenter Unsustained Tachycardia
Trial
RR  relative risk
SCD-HeFT  Sudden Cardiac Death in Heart
Failure Trialave to address the issue of sudden cardiac death based on Ahe available data, without the benefit of meta-analyses. The
ocus of this pooled analysis is to provide an updated review
f all-cause mortality from the recently published and
resented clinical trials. Our aim is to provide an updated
nalysis of available data from randomized controlled trials
nd to present a perspective on the effect of ICD implan-
ation in prevention of death in patients with LV systolic
ysfunction, irrespective of etiology of the LV dysfunction
nd the QRS duration.
REVIOUS STUDIES
he five trials that had been included in previous meta-
nalyses were the MADIT (14), the Coronary Artery
ypass Graft Patch (CABG-Patch) trial (15), the MUSTT
16), the Cardiomyopathy Trial (CAT) (17), and the
ADIT II (18). The trial design, etiology of LV dysfunc-
ion, ejection fraction, additional risk marker used for
nclusion, and follow-up duration are detailed for each of
he trials in Table 1.
The MADIT trial tested the hypothesis that an ICD
ould improve survival for patients with ischemic heart
isease at high risk of arrhythmic death (14). This trial used
picardial leads in one-half of the patients and transvenous
ndocardial leads in the other half. In this trial the mortality
ate in the ICD group was 16% versus 39% in patients
andomized to the conventional treatment group after 27
onths of follow-up (RR reduction of 59%, absolute risk
eduction 23%, p  0.009) (14).
The CABG-Patch trial tested the role of prophylactic
CD implantation in patients undergoing elective coronary
rtery bypass surgery (15). In contrast to other trials and
imilar to one-half the patients in the MADIT trial, the
efibrillation leads were epicardial patches placed at the
ime of coronary artery bypass surgery. The mortality rate in
he ICD-treated patients was 23% and 21% in the control
atients, with no difference in all-cause mortality at 32
onths (p  0.64) (14).
The MUSTT trial was a randomized trial of two treat-
ent strategies (EP-guided versus empiric) for patients with
oronary artery disease and unsustained ventricular tachy-
ardia, and ICD use was not randomized (16). The five-year
ortality rate in the EP-guided group was 42%, which
ompared with 48% in the non–EP-guided group (p 
.06). However, a nonrandomized comparison of patients in
he EP-guided arm demonstrated that the patients who
eceived an ICD had significantly lower all-cause mortality
t five years (24%) than those who did not receive a device
55%) (RR reduction of 56%, absolute risk reduction 31%,
 0.001) (16).
The CAT study included patients with dilated, nonisch-
mic cardiomyopathy. Enrollment in this very small trial
as terminated early because the interim analysis showed
hat the overall one-year mortality rate for all patients was
nly 5.6% and well below the assumed value of 30%.
ccording to the protocol, the randomization was stopped,
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Implantable Cardioverter-Defibrillator Therapy December 7, 2004:2166–72nd all randomly assigned patients completed the scheduled
ollow-up period of two years. After two years the mortality
ate was 26% in the ICD patients and 50% in the control
able 1. Summary of Defibrillator Studies
Trial Design Patients
ADIT Multicenter RCT of
ICD vs.
antiarrhythmic
drugs as
conventional
therapy
196 patients with MI 3
wk before entry and
EF 0.35
ABG-Patch Multicenter RCT of
ICD vs. no
antiarrhythmic
drugs as
conventional
therapy
1,055 patients undergoing
CABG with EF 0.35
USTT Multicenter RCT of
strategy of EP-
guided vs. empiric
therapy
704 patients with ischemic
cardiomyopathy with
EF 0.40
AT Multicenter RCT of
ICD vs.
conventional
therapy
104 patients with recent
onset nonischemic
cardiomyopathy with
EF 0.30
ADIT II Multicenter RCT of
ICD vs. optimized
medical therapy
1,232 patients with a prior
myocardial infarction and
EF 0.30
MIOVIRT Multicenter RCT of
ICD vs.
amiodarone as
medical therapy
101 patients with
nonischemic
cardiomyopathy with
EF 0.35
OMPANION Multicenter RCT of
CRT vs. CRT-D
vs. optimized
medical therapy
1,520 patients with ischemic
and non-ischemic
cardiomyopathy with
EF 0.35
EFINITE Multicenter RCT of
ICD vs. standard
medical therapy
458 patients with
nonischemic
cardiomyopathy with
EF 0.36
INAMIT Multicenter RCT of
ICD vs. optimized
medical therapy
674 patients within 6–40
days of myocardial
infarct ischemic with
EF 0.35
CD-HeFT Multicenter RCT of
ICD vs optimized
medical therapy
vs. optimized
medical therapy
with amiodarone
2,521 patients with ischemic
and nonischemic
cardiomyopathy with
EF 0.35
AD  antiarrhythmic drugs; AMIOVIRT  Amiodarone versus Implantable C
ABG-Patch  Coronary Artery Bypass Graft Patch trial; CAT  Cardiomyopathy Tr
ith Left Ventricular Systolic Dysfunction trial; CRT  cardiac resynchronization thera
efibrillators In Non-Ischemic cardiomyopathy Treatment Evaluation trial; DINAM
lectrophysiology; ICD  implantable cardioverter defibrillator; MADIT  Multicen
ulticenter Unsustained Tachycardia Trial; RCT randomized controlled trial; SAECG
eart Failure Trial; VT  ventricular tachycardia.atients (p  0.554) (17). fThe MADIT II trial tested the hypothesis that prophy-
actic ICD implantation would reduce mortality in patients
ith ischemic cardiomyopathy without the requirement of
Additional Risk
Marker Interventions
Average
Follow-Up
symptomatic
unsustained VT
unrelated to an
acute MI with
inducible VT not
suppressed after iv
procainamide
95 randomized to ICD,
101 to AAD (primarily
amiodarone)
27 mo
bnormal SAECG 446 randomized to ICD,
454 to usual care - no
protocol-driven AAD
therapy instituted
32 mo
nducible, sustained
ventricular
tachyarrhythmias
351 assigned EP-guided
therapy (161 ICDs,
without randomization);
353 to receive no
antiarrhythmic therapy
Median 39 mo
— 50 randomized to ICD,
54 to conventional
therapy
23 mo
— 742 randomized to ICD,
490 to optimized medical
therapy
20 mo
onsustained
ventricular
tachycardia
51 randomized to ICD,
52 to amiodarone
24 mo
RS duration
120 ms
495 randomized to CRT-D,
617 to CRT
16 mo
onsustained
ventricular
tachycardia or
frequent premature
ventricular
complexes
229 randomized to ICD,
229 to standard medical
therapy
29 mo
epressed heart rate
variability
332 randomized to ICD,
342 to optimized medical
therapy
30 mo
— 847 randomized to
optimized medical
therapy, 845 to optimized
medical therapy and
amiodarone, 829 to an
ICD
48 mo
rter-Defibrillator Randomized Trial in patients with nonischemic cardiomyopathy;
MPANION  Comparison of Medical therapy; Pacing, and Defibrillation in Patients
T-D  cardiac resynchronization therapy with defibrillation capability; DEFINITE 
Defibrillator in Acute Myocardial Infarction Trial; EF  ejection fraction; EP 
utomatic Defibrillator Implantation Trial; MI  myocardial infarction; MUSTT 
nal-averaged electrocardiogram; SCD-HeFT Sudden Cardiac Death in Patients withA
A
I
N
Q
N
D
ardiove
ial, CO
py; CR
IT 
ter A
 sigurther risk stratification (18). The mortality rate was 19.8%
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December 7, 2004:2166–72 Implantable Cardioverter-Defibrillator Therapyn the conventional therapy group and 14.2% in the ICD
roup at 20 months (RR reduction of 28%, absolute risk
eduction of 5.6%, p  0.016).
These five trials were included in two previous meta-
nalyses that showed a relative reduction in all-cause mortality
f 34% (p  0.03) (2,3). Both analyses included the MUSTT
rial, which was not a randomized comparison of ICD use
19,20). Sensitivity analysis of the meta-analysis performed by
ee et al. (3) indicated that the primary prevention analysis was
ensitive to the MUSTT trial, which was not a randomized
omparison of the ICD versus conventional therapy. Exclud-
ng the MUSTT trial, the RR of arrhythmic death was 0.45 (p
0.01), but the risk of all-cause mortality (RR 0.74; 95%
onfidence interval [CI] 0.51 to 1.08) was no longer signifi-
antly reduced (p  0.12) (3).
ECENT STUDIES
ince the publication of the previous meta-analyses, data from
ve additional primary prevention trials have been reported:
) the Amiodarone Versus Implantable Cardioverter-
efibrillator Randomized Trial (AMIOVIRT) in patients
ith nonischemic cardiomyopathy (9); 2) Comparison of
edical Therapy, Pacing, and Defibrillation in Patients With
eft Ventricular Systolic Dysfunction Trial (COMPANION)
10); 3) Defibrillators In Non-Ischemic Cardiomyopathy
reatment Evaluation Trial (DEFINITE) (11); 4) Defibrilla-
or in Acute Myocardial Infarction Trial (DINAMIT) (12);
nd 5) Sudden Cardiac Death in Heart Failure Trial (SCD-
eFT) (13). The key particulars of these trials are summarized
n Table 1.
The AMIOVIRT trial evaluated patients with nonischemic
ilated cardiomyopathy. The trial was terminated after a
re-specified stopping rule for futility was reached. Survival at
years was 88% in the ICD group and 87% in the control
roup, significantly higher than had been predicted, with no
ifference in mortality between groups (p  0.8) (9).
The COMPANION trial was a prospective, randomized
rial that compared optimized medical therapy, optimized
edical therapy with cardiac resynchronization therapy
sing biventricular pacing (CRT), and optimized medical
herapy with CRT and ICD capability (CRT-D) in patients
ith either ischemic or nonischemic cardiomyopathy.
ence, any difference in all-cause mortality between the
RT and the CRT-D groups provides insight into the
tility of prophylactic ICD therapy in this patient popula-
ion. At 12 months, the mortality rate was 19% in the
ptimized medical therapy group, 15% in the CRT group,
nd 12% in the CRT-D group. The relative reduction in
ll-cause mortality compared with optimized medical ther-
py was 24% with CRT (p  0.06) and 36% with CRT-D
p  0.004) (10).
The DEFINITE trial included patients with nonisch-
mic cardiomyopathy. The mortality rate in patients ran-
omized to optimized medical therapy was 13.8% compared aith 8.1% in patients randomized to the ICD, over mean
ollow-up of 29 months (RR reduction of 41%, absolute risk
eduction 5.7%, p  0.06) (11).
The DINAMIT trial enrolled patients within 40 days of
yocardial infarction to a treatment strategy of optimized
edical therapy either with or without an ICD. These
atients had no difference in all-cause mortality (7.5% in the
CD group vs. 6.9% in the non-ICD group) at a mean
ollow-up of 2.5 years (p  0.66) (12).
The SCD-HeFT trial randomized 2,521 patients with
schemic or nonischemic cardiomyopathy to optimized
eart failure therapy including beta-blockers, angiotensin-
onverting enzyme (ACE) inhibitors, and spironolactone;
ptimized heart failure therapy with the addition of amio-
arone; or medical treatment with the addition of an ICD.
fter a median follow-up of four years, the mortality rate
as 22% in the ICD group, 28% in the amiodarone group,
nd 29% in the control group. This resulted in a 24% RR
eduction and a 7% absolute risk reduction in the all-cause
ortality in the ICD group as compared with optimized
edical therapy alone (p  0.007) (13).
OOLED ANALYSIS
ethods. The number of patients who died in the ICD
nd non-ICD groups was extracted from published data and
resented abstracts. The RR and RR difference with 95%
Is using fixed and random effects models were calculated
or the trials separately and for all the trials in the overall
nalysis (20,21). Statistical heterogeneity between studies
as identified using the chi-square statistic. When pooled
nalysis resulted in significant heterogeneity, the random
ffects model is presented. Conversely, in the absence of
eterogeneity between studies, the fixed effects analysis is
eported. Sensitivity analysis was performed to determine
hether the overall conclusion of ICD effectiveness was
obust (i.e., not overly influenced by an individual random-
zed trial). We re-analyzed the pooled data after sequentially
emoving each trial from the pooled analysis.
esults. Figure 1 demonstrates the RR reduction from 10
ifferent trials. Among the 3,530 patients randomized to
eceive an ICD, there were 647 deaths, compared with 976
eaths in the 3,723 patients randomized to a non-ICD
roup. When the deaths from all the trials were pooled
sing the random effects model, there was a 25% relative
eduction in all-cause mortality with the ICD (p  0.003)
95% CI 9% to 37%). All-cause mortality in the control
roup for the 10 studies was 26.4%, compared with 18.5%
n the ICD group (absolute mortality reduction of 7.9%).
Table 2 demonstrates the results of sensitivity analysis.
he conclusions reached are not sensitive to the exclusion of
ny one trial as evidenced by the 95% CI of the odds ratios
nd p values. Thus, the conclusions reached by the pooling
re robust.
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ur analysis indicates that implantation of an ICD for
rimary prevention of death in patients with LV systolic
ysfunction irrespective of etiology and QRS duration
ignificantly reduces overall mortality at intermediate-term
ollow-up. This finding is not sensitive to the exclusion of
ny one of the trials from the pooled analysis.
It can be argued that some of the trials included in the
ooled analysis are confounded by other variables that affect
udden cardiac death. Veenhuyzen et al. (22) quantified the
ffect of CABG surgery on mortality in the Studies Of Left
entricular Dysfunction (SOLVD) trials. Prior CABG
urgery was associated with a 25% reduction in risk of death
nd a 46% reduction in risk of sudden death independent of
jection fraction and severity of heart failure symptoms.
hen they applied these results to a group of patients with
igure 1. Death from all causes in all available primary prevention trials. D
ICD) trials, pooled in a random effects model. For each randomized trial, th
epresent the point estimates of the relative risk (RR) for individual studies
R is 0.75, which significantly favors treatment with the defibrillator (p 
he midpoint of the diamond represents the point estimate of the RR. S
able 2. Sensitivity Analysis
tudy Removed
Relative
Risk 95% CI
Overall
Effect
(p value)
MIOVIRT 0.75 (0.62–0.91) p  0.003
ABG-Patch 0.72 (0.59–0.86) p  0.0004
AT 0.75 (0.61–0.91) p  0.004
OMPANION 0.74 (0.60–0.92) p  0.006
EFINITE 0.76 (0.62–0.93) p  0.007
INAMIT 0.72 (0.59–0.87) p  0.0007
ADIT 0.79 (0.66–0.94) p  0.009
ADIT II 0.76 (0.61–0.94) p  0.01
USTT 0.81 (0.69–0.95) p  0.009
CD-HeFT 0.75 (0.59–0.94) p  0.01
emoval of each study followed by re-analysis of the pooled relative risk and 95%
onfidence interval (CI) in the remaining trials is shown. The results suggest that the
ignificant overall benefit of defibrillators on all-cause mortality in primary prevention
s preserved independent of the effects of any individual study.
Abbreviations as in Table 1.V dysfunction who had not undergone prior surgery
Coronary Artery Surgery Study [CASS] registry), the
redicted annual rates of death (8.2%) and sudden death
2.4%) were similar to those observed in the CABG-Patch
rial (7.9% and 2.3%, respectively). Those investigators
oncluded that prior CABG surgery is associated with a
ignificant independent reduction in mortality that could
ave confounded the effect of ICD therapy in the CABG-
atch trial (22). The DINAMIT trial evaluated patients
mmediately after myocardial infarction. The confounding
ffect of ICD shock therapy, ACE inhibition, beta-blocker
herapy, and revascularization on the ejection fraction over
ime is difficult to quantify in this population. However, it
ust be stated that the fact that the CABG-Patch and
INAMIT trials included treatment effects that may have
onfounded benefits of an ICD are supposition and merely
ypothesis generating. The MUSTT trial was not a ran-
omized trial of ICD therapy, a fact that is known to
nvalidate pooled analyses when included. Hence, for these
easons we excluded these three trials (CABG-Patch, DI-
AMIT, and MUSTT) and repeated the pooled analysis.
igure 2 demonstrates the seven remaining trials and the
elative mortality risk reduction. When the deaths from
hese seven trials were pooled, there was a 26% reduction in
ll-cause mortality with the ICD (p  0.00001) (95% CI
7% to 33%). All-cause mortality in the control group for
he seven trials was 24.1%, compared with 17.5% in the
CD group (absolute mortality reduction of 6.6%). Al-
hough the test for heterogeneity (the assessment of differ-
nce in treatment effect) was significant before exclusion of
hese trials (p  0.0005) (Fig. 1), after exclusion of these
rials the test for heterogeneity was no longer significant (p
rom all causes in the 10 prophylactic implantable cardioverter-defibrillator
ber of deaths (n) and the number assigned (N) are shown. The rectangles
the 95% confidence intervals (CIs) are shown as bars. The overall pooled
3). The horizontal tips of the black diamond represent the 95% CI, and
Abbreviations box for trial acronyms.eath f
e num
, and0.39) (Fig. 2). This supports the removal of the CABG-
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December 7, 2004:2166–72 Implantable Cardioverter-Defibrillator Therapyatch, DINAMIT, and MUSTT trials from a pooled
nalysis of prophylactic ICDs in patients with impaired LV
ystolic function. Thus, the strategy of ICD implantation
or primary prevention of death is consistent and significant
or the seven randomized trials listed in Figure 2.
CD therapy and other accepted therapies in LV dys-
unction. The absolute mortality reduction of 7.9%
number needed to treat  13) by prophylactic ICDs
hould be compared with a 6.1% reduction afforded by
CE inhibitors (23) and a 4.4% by beta-blockers (24) in
atients with LV systolic dysfunction at intermediate-
erm follow-up. Approximately 90% of the patients in
his pooled analysis were from later trials (MADIT II,
CD-HeFT, COMPANION, DEFINITE) in which
here was protocol-specified optimized medical therapy
ith beta-blockers and ACE inhibitors for LV dysfunc-
ion. Hence, the mortality reduction provided by ICDs
as in addition to the reductions afforded by beta-
lockers and ACE inhibitors. Like aldosterone antago-
ists, which reduce mortality by 2.3% when added to
eta-blockers and ACE inhibitors (25), ICDs offer ben-
fits that are additive to state-of-the art medical
reatment.
ost considerations. The results of our study identify the
ffect of the ICD as primary preventative therapy on the risk
f mortality with greater precision than a previously pub-
ished meta-analysis (3). Owens et al. (26) described the
ide range of incremental cost-effectiveness that could
esult in sensitivity analyses that vary the estimated RR
eduction with the ICD. The narrower range of ICD effect
n this study allows for greater precision in estimating the
ost-effectiveness of this therapy. The cost of treating
atients with systolic dysfunction with ICDs is nonlinear as
igure 2. Death from all causes in nonselective primary prevention trials. D
USTT) pooled in a random effects model. For each randomized trial, the
epresent the point estimates of the RR for individual studies, and the 95%
reatment with the defibrillator (p  0.00001). The horizontal tips of t
epresents the point estimate of the RR. See the Abbreviations box for trhere is a high initial device cost, hospitalization cost, and cower follow-up cost. Not only is ICD therapy nonlinear
ith regard to cost, as shown by Salukhe et al. (27), it is
onlinear with regard to life-years saved and number of
atients needed to be treated to save one life. The benefit of
he strategy of implanting a prophylactic ICD in patients
ith LV systolic dysfunction is expected to rise dramatically
ver time. Salukhe et al. (27) have shown that at least for the
rst three years, this benefit rises as the square of implant
uration. This exponential growth of benefit suggests that
ur analysis represents a conservative conclusion of the
enefit of a strategy of implanting ICDs for the prevention
f death in patients with LV systolic dysfunction.
ndividualization of ICD therapy. Although prophylactic
CD implantation improved overall mortality in the studies
eviewed, these devices are unlikely to be appropriate for all
atients who meet the entry criteria. Just as some patients
ith LV systolic dysfunction do not tolerate beta-blockers
ecause of bradycardia or hypotension, or ACE inhibitors
ecause of cough or hyperkalemia, there are patients who
ay not be ideal candidates for a prophylactic ICD. Indeed,
he care of patients with LV systolic dysfunction must be
ndividualized, after discussion with them. Some patients
ay elect not to undergo an operative procedure even when
ully informed of the expected survival benefit. For example,
atients with intractable congestive heart failure may decline
CD implantation because of concerns regarding prolonga-
ion of a very poor quality of life. Others may have such
nxiety regarding defibrillation shocks (that the expectation
f an increased probability of survival is outweighed by an
dverse impact of the device on their quality of life). In
ddition, there are often comorbid conditions that have
ompeting effects on mortality that must be considered by
oth the patient and the physician. Finally, patients entering
from all causes in seven trials (excluding CABG-Patch, DINAMIT, and
ber of deaths (n) and the number assigned (N) are shown. The rectangles
re shown as bars. The overall pooled RR is 0.74, which significantly favors
ack diamond represent the 95% CI, and the midpoint of the diamond
onyms.eath
num
CIs alinical trials may be selected for the likeliness they will
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hether unselected populations will have the same degree
f benefit from prophylactic ICD implantation remains to
e determined.
ONCLUSIONS
n the basis of currently available clinical data, implanta-
ion of an ICD for primary prevention of death in patients
ith LV systolic dysfunction provides a significant reduc-
ion in overall mortality at intermediate-term follow-up.
he absolute mortality reduction is additive to accepted
rug therapies for LV systolic dysfunction. However, just
ike other therapies for LV systolic dysfunction, the appli-
ation of this treatment needs to be individualized for each
atient. The ICD therapy differs substantially from drug
herapy, particularly from the standpoint of initial cost. The
ptimal use of this therapy will require better risk stratifi-
ation methods or lowering of initial device cost.
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